Severe atopic dermatitis in a 21-month-old boy successfully treated with dupilumab

Daniel Mazzoni1, Yolanka Lobo1, David Levitt2

  • 1Department of Dermatology, Queensland Children's Hospital, Brisbane, Queensland, Australia.

Insights

Dupilumab offers a new targeted treatment for severe atopic dermatitis (AD). This case study shows its successful use in a 21-month-old child with severe, difficult-to-treat AD.

Area of Science:

  • Dermatology
  • Pediatric Allergy and Immunology
  • Pharmacology

Background:

  • Severe atopic dermatitis (AD) poses significant challenges in young children.
  • Limited data exists on the efficacy and safety of novel systemic treatments like dupilumab in this age group.
  • Recalcitrant AD in infants requires effective and safe therapeutic options.